Earnings Show a Mixed Bag for Mass Spec in Q1 as Vendors Anticipate Release of Capital Budgets | GenomeWeb

NEW YORK (GenomeWeb News) – With first quarter results in for major life science mass spec vendors, a mixed picture has emerged as academic, government, and pharma spending delays, particularly in the US and China, countered stronger performance in European markets.

Waters and Agilent both posted flat revenues for the quarter ended March 31, while Danaher reported a 5 percent rise, Bruker an 8 percent rise, and Thermo Fisher Scientific a 22 percent jump in revenues year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.